The addition of the bispecific T-cell engager molecule blinatumomab (an anti-CD19 and anti-CD3 single-chain molecule) to therapy for newly diagnosed standard-risk (as defined by the National ...

We studied the safety and efficacy of blinatumomab, a bispecific T-cell engager molecule targeting CD19, in infants with KMT2A-rearranged ALL. Thirty patients younger than 1 year of age with newly ...

Implementing Evidence-Based Strategies to Improve Pediatric Oncology Infection Management Blinatumomab has rapidly emerged as a cornerstone in the treatment of B-cell ALL (B-ALL) across age and risk ...

Opens in a new tab or window The randomized phase III AALL1731 trial presented at the American Society of Hematology annual meeting showed that adding the bispecific T-cell engager blinatumomab ...

The breakthrough, described in a New England Journal of Medicine paper and presented at a conference in mid-December, is called blinatumomab, an immunotherapy drug delivered to patients over a 28 ...

NEW ORLEANS — Blinatumomab extended survival when combined with chemotherapy for adults with minimal residual disease-negative, B-lineage acute lymphoblastic leukemia, according to a study ...

Table 1. Indications for Blinatumomab in Chemotherapy and HSCT Groups Severe toxicity (n = 53) 18 sepsis (6 = G3, 12 = G4), the majority (n = 11) of whom required intensive care 13 invasive fungal ...

Blinatumomab has emerged as one part of the solution for some patients. It is approved by the FDA for certain patients with CD19-positive BCP-ALL, including patients with MRD-positive status in ...

Bringing the bispecific T-cell engager into the frontline consolidation phase "redefines the standard of care" for patients with B-ALL, an investigator said. FDA has approved blinatumomab, a ...

The practice-changing finding is from the randomized phase 3 study E1910, which evaluated blinatumomab immunotherapy in patients who were in remission and tested negative for measurable residual ...